coin-img-ETHETH-2.27%coin-img-SOLSOL-1.89%coin-img-XRPXRP-3.67%coin-img-BTCBTC-1.78%coin-img-USDCUSDC-0.01%coin-img-TRXTRX+0.82%coin-img-DOGEDOGE-2.97%coin-img-HYPEHYPE-3.61%coin-img-ETHETH-2.27%coin-img-SOLSOL-1.89%coin-img-XRPXRP-3.67%coin-img-BTCBTC-1.78%coin-img-USDCUSDC-0.01%coin-img-TRXTRX+0.82%coin-img-DOGEDOGE-2.97%coin-img-HYPEHYPE-3.61%coin-img-ETHETH-2.27%coin-img-SOLSOL-1.89%coin-img-XRPXRP-3.67%coin-img-BTCBTC-1.78%coin-img-USDCUSDC-0.01%coin-img-TRXTRX+0.82%coin-img-DOGEDOGE-2.97%coin-img-HYPEHYPE-3.61%coin-img-ETHETH-2.27%coin-img-SOLSOL-1.89%coin-img-XRPXRP-3.67%coin-img-BTCBTC-1.78%coin-img-USDCUSDC-0.01%coin-img-TRXTRX+0.82%coin-img-DOGEDOGE-2.97%coin-img-HYPEHYPE-3.61%
user-avatar
The New York Times

Novartis’ experimental heart drug pelacarsen fails in major clinical trial

AI Market Summary
Novartis said its experimental cardiovascular drug pelacarsen failed in a large clinical trial, undermining a widely anticipated Lp(a)-targeting treatment category. The result raises uncertainty around Novartis' cardiovascular pipeline and could pressure biotech/pharma sentiment, particularly for programs tied to Lp(a) risk reduction. In the near term, markets may reprice expected future revenue from pelacarsen and reassess probability-of-success assumptions across similar assets.
Impact level
● Medium
Affected assets
NCSKONDS2USD/USDT-0.77%
AI Insight · NCSKONDS2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Novartis said its experimental cardiovascular drug pelacarsen failed in a large clinical trial. The treatment had been widely viewed as a potential breakthrough for preventing heart attacks, strokes and cardiovascular deaths. The setback surprised cardiologists who had been expecting Lp(a)-targeting drugs to play a major role in prevention.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Finance

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.